Creyon’s proprietary aptamer platform enables tissue-specific delivery of RNA therapies.
Creyon has demonstrated proof-of-concept (POC) in immunology, central nervous system (CNS), and neuromuscular disease areas and is expanding into other therapeutic areas.
Aptamer-mediated delivery enables the targeting of oligonucleotide payloads (e.g., small interfering RNA [siRNA], antisense oligonucleotide [ASO]) and lipid nanoparticles (LNPs) to activated immune cells.
Lead transferrin receptor (TfR)-targeted aptamer enables delivery of oligonucleotide payloads (e.g., siRNA and ASO) across the blood brain barrier, achieving broad CNS distribution and target gene knockdown in vivo.
Lead aptamer–ASO conjugate demonstrates in vivo POC, validating tissue-specific delivery and functional activity.
Building a Versatile Pipeline Through Innovation & Collaboration
Creyon advances a dual strategy:
Building a wholly owned pipeline of novel therapeutics
Pursuing high-value partnerships to apply its platform across additional disease areas